<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl1">
 <label>Table 1</label>
 <caption>
  <p>Mechanisms to improve financing for hepatitis B elimination activities</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Mechanism</th>
    <th>Approaches</th>
    <th>Examples</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="4">Reduction in treatment costs</td>
    <td>Price negotiations with pharmaceutical manufacturers for hepatitis treatment and diagnostics</td>
    <td>Australia, Brazil, Thailand(16, 26)</td>
   </tr>
   <tr>
    <td>Local production of generic medicines</td>
    <td>China, India(26)</td>
   </tr>
   <tr>
    <td>Inclusion of diagnostics and medications under UHC, list on Essential medicines and Essential diagnostics list</td>
    <td>Rwanda, Pakistan, Brazil(26)</td>
   </tr>
   <tr>
    <td>Utilisation of TRIPs flexibilities to access affordable medicines and diagnostics</td>
    <td>Thailand (hepatitis C medications)(
     <xref rid="bib26" ref-type="bibr">26</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="3">Maximise effectiveness of public health spending</td>
    <td>Integration of viral hepatitis into existing health services for HIV, maternal child health programmes, and non-communicable diseases</td>
    <td>Hepatitis B: South Africa(85) , Brazil(26); Hepatitis C: Egypt, Pakistan(16, 20)</td>
   </tr>
   <tr>
    <td>Adopting an investment case approach to guide investments</td>
    <td>South Africa (
     <xref rid="bib85" ref-type="bibr">85</xref>), China(26, 36), Senegal(86), The Gambia(33)
    </td>
   </tr>
   <tr>
    <td>Leverage WHO regional technical and resource support for viral hepatitis and other disease elimination activities to improve efficiency and effectiveness</td>
    <td>Russian Federation (strategic planning), Ethiopia (surveillance reporting), Pacific Islands and Territories (vaccination)(
     <xref rid="bib16" ref-type="bibr">16</xref>)
    </td>
   </tr>
   <tr>
    <td rowspan="5">Share costs with other strategies</td>
    <td>Immunization and blood safety</td>
    <td>Rwanda, Brazil, China (
     <xref rid="bib26" ref-type="bibr">26</xref>)
    </td>
   </tr>
   <tr>
    <td>Co-infection with HIV and service delivery</td>
    <td>Rwanda, Brazil, South Africa (
     <xref rid="bib26" ref-type="bibr">26</xref>)
    </td>
   </tr>
   <tr>
    <td>Prevention of mother-to-child transmission including investment to increase in-hospital births through MDG funding pools</td>
    <td>China(26), Fiji (
     <xref rid="bib60" ref-type="bibr">60</xref>), Malaysia(16)
    </td>
   </tr>
   <tr>
    <td>Hepatitis C programmes</td>
    <td>Myanmar, Mongolia(16)</td>
   </tr>
   <tr>
    <td>Non-communicable disease programmes</td>
    <td>Egypt (hepatitis C)</td>
   </tr>
   <tr>
    <td rowspan="4">Increase innovation to increase efficiencies over time</td>
    <td>Dried blood sampling</td>
    <td>The Gambia (
     <xref rid="bib33" ref-type="bibr">33</xref>)
    </td>
   </tr>
   <tr>
    <td>Non-specialist care and telemedicine</td>
    <td>Australia(60, 87)</td>
   </tr>
   <tr>
    <td>PoC multi-disease diagnostic platforms (eg GenXpert) to increase hepatitis B testing capacity</td>
    <td>Rwanda(16)</td>
   </tr>
   <tr>
    <td>Cross-sectoral government ministry partnerships</td>
    <td>South Africa- Ministry of Health and Ministry of Finance(16)</td>
   </tr>
   <tr>
    <td rowspan="5">International donor investment</td>
    <td>Hepatitis B vaccination</td>
    <td>GAVI Alliance hepatitis B vaccination program (birth dose soon to be added to global program)(
     <xref rid="bib59" ref-type="bibr">59</xref>); utilization of MDG4 and 5 funds to increase vaccination coverage including birth dose- Fiji, Brazil, Rwanda (
     <xref rid="bib26" ref-type="bibr">26</xref>)
    </td>
   </tr>
   <tr>
    <td>Prevention of mother-to-child transmission including investment to increase in-hospital births</td>
    <td>Public- private partnerships-China (
     <xref rid="bib26" ref-type="bibr">26</xref>) (Zeshan Foundation and Rotary International with Ministry of Health)
     <break/>China – GAVI -MoH partnership
     <break/>Global Fund
    </td>
   </tr>
   <tr>
    <td>Provision of effective treatment</td>
    <td>Rwanda – CHAI; NGO and pharma funding partnership with MoH, Fiji, Kiribati, Samoa and Tonga (Gilead, HepB Free)
     <break/>Universal health coverage and essential medicines list- China, Brazil, Rwanda (
     <xref rid="bib16" ref-type="bibr">16</xref>)
    </td>
   </tr>
   <tr>
    <td>Low-cost diagnostics</td>
    <td>China, India
     <break/>Unitaid is partnering with the Foundation for Innovative Diagnostics (FIND) through a US $38 million grant to support the development point-of-care diagnostics(88)
     <break/>Development and validation of in-house HBV DNA assays with international support– The Gambia(69)
    </td>
   </tr>
   <tr>
    <td>Regional strategy support</td>
    <td>Colombia, Brazil, Chile – leveraging the PAHO Strategic Fund to cover cost of diagnostics and treatment to increase affordability(16)</td>
   </tr>
   <tr>
    <td rowspan="4">Innovative blended financing models</td>
    <td>Pooled financing: Bringing together development and commercial actors to pool financing and increase scale up of blended finance models.</td>
    <td>China- utilization of public-private partnerships to roll-out universal infant hepatitis B vaccination and catch-up programs, supported by the GAVI Alliance (
     <xref rid="bib26" ref-type="bibr">26</xref>)
     <break/>Rwanda- Use of novel blend of private and public insurance and pooled community-based microfinancing to support treatment costs (
     <xref rid="bib16" ref-type="bibr">16</xref>, 
     <xref rid="bib26" ref-type="bibr">26</xref>)
     <break/>Global Procurement Fund (GPRO) (
     <xref rid="bib31" ref-type="bibr">31</xref>)- works with participating countries to pool medication orders from member countries and uses international competitive bidding to purchase products, working solely with manufacturers that operate either with a license from the originator-companies or those with a license from the Medicines Patent Pool.
     <break/>Civil society and regional public partnerships- Eastern Europe to fund STI prevention services(16)
    </td>
   </tr>
   <tr>
    <td>Results-based financing: Create market incentives to achieve critical social outcomes by only paying when results are achieved. Two main types: 
     <italic>Performance-based financing</italic> targets the supply side, whereas c
     <italic>onditional cash transfers</italic> target the demand side of a given market.
    </td>
    <td>Health Systems Strengthening support (HSS) and the Immunisation Services Support (ISS) of the GAVI Alliance (
     <xref rid="bib2" ref-type="bibr">2</xref>)
     <break/>The Global Fund has implemented a Results Based Financing model in Rwanda called the ‘National Strategy Financing’ to incentivize results and efficiency.
    </td>
   </tr>
   <tr>
    <td>Social and Development Impact Bonds: Draw on elements of impact investing or blended finance as well as public-private partnerships and allow outcome funders to pay directly for the achievement of outputs or outcomes rather than for inputs or compliant behaviour. Investors provide upfront risk capital (opportunity for return), play a critical role in improving service delivery by bringing private sector discipline into practice.</td>
    <td>The International Finance Facility for Immunization uses donor pledges to issue vaccine bonds to raise money for Gavi Alliance.</td>
   </tr>
   <tr>
    <td>Dedicated hepatitis fund: Create a global viral hepatitis fund to leverage resources and cultivate synergies through innovative public-private partnerships, and catalyse action on viral hepatitis; primarily support the most-affected countries and communities where national health systems cannot address hepatitis epidemics. Specific high-impact activities would be supported through the structures of the UN World Health Assembly and Regional Committees.</td>
    <td>The Hepatitis Fund (World Hepatitis Alliance)</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>*All activities and examples are for hepatitis B unless otherwise stated.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
